

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-38. Cancelled

39. (Previously Presented) An isolated nucleic acid coding for the human cell volume-regulated kinase (h-sgk) consisting of the amino acid sequence shown in SEQ ID NO:2.

40. (Previously Presented) An isolated nucleic acid consisting of the nucleotide sequence shown in SEQ ID NO:1.

41. (Previously Presented) A nucleic acid encoding an amino acid sequence consisting of approximately the region of amino acid position 313 to 431 of the amino acid sequence as claimed in claim 40.

42. (Previously Presented) A nucleic acid consisting of approximately the region of nucleotide position 980 to 1480 of the nucleic acid sequence as claimed in claim 40.

43. (Currently Amended) A nucleic acid, which is capable of hybridizing [under conditions of Northern hybridization or *in situ* hybridization to an RNA, which, either], in the sense or antisense direction, [consisting of the] to nucleotide sequences [sequences shown in SEQ ID NO:1, the capability of hybridizing being confined to approximately] in the region corresponding to nucleotide position 980 to 1480 of SEQ ID NO:1.

44. (Previously Presented) A nucleic acid fragment coding for an immunogenic fragment of the human cell volume-regulated kinase (h-sgk) consisting of at least one of the following amino acid sequences:

DPEFTEEPVPNSIGKSPDS (SEQ ID. NO: 3)

EAFLGFSYAPPTDSFL (SEQ ID. NO: 4)

45. (Previously Presented) A composition comprising the nucleic acid as claimed in claim 39 and a pharmaceutically acceptable carrier.

46. (Previously Presented) A composition comprising the nucleic acid as claimed in claim 40 and a pharmaceutically acceptable carrier.

47. (Previously Presented) A composition comprising the nucleic acid as claimed in claim 41 and a pharmaceutically acceptable carrier.

48. (Previously Presented) A composition comprising the nucleic acid as claimed in claim 42 and a pharmaceutically acceptable carrier.

49. (Previously Presented) A composition comprising the nucleic acid as claimed in claim 43 and a pharmaceutically acceptable carrier.

50. (Previously Presented) A composition comprising the nucleic acid as claimed in claim 44 and a pharmaceutically acceptable carrier.

51. (New) The nucleic acid according to claim 43, wherein the capability of hybridizing is confined to approximately said region.

52. (New) A composition comprising the nucleic acid in claim 44 and a pharmaceutically acceptable carrier.